PMID- 9043940
OWN - NLM
STAT- MEDLINE
DCOM- 19970428
LR  - 20190920
IS  - 0162-3109 (Print)
IS  - 0162-3109 (Linking)
VI  - 35
IP  - 3
DP  - 1997 Jan
TI  - Vancomycin down-regulates lipopolysaccharide-induced tumour necrosis factor alpha 
      (TNF alpha) production and TNF alpha-mRNA accumulation in human blood monocytes.
PG  - 265-71
AB  - The cytokines play an important role in the cascade of the pathological events 
      leading to septic shock. The TNF alpha produced by monocytes/macrophages upon 
      stimulation with bacterial fragments may contribute to induction of this cytokine 
      cascade. Moreover, the antibiotics used for antimicrobial therapy may cause the 
      increase of TNF alpha production due to massive bacterial killing and exposure of 
      monocytes/macrophages to bacterial cell constituents. To investigate the effect 
      of Vancomycin on TNF alpha production, an in vitro model of LPS-stimulated 
      monocytes was used. The level of TNF alpha protein or TNF biological activity 
      were tested in the culture supernatants of monocytes with LPS. Vancomycin 
      down-regulated, in dose-dependent manner, the TNF alpha production. Vancomycin 
      also inhibited TNF alpha-mRNA accumulation in LPS-stimulated monocytes, as 
      assessed by fluorescence in situ hybridization (FISH) in cell suspension. The 
      down-regulation of TNF alpha production in LPS-stimulated monocytes may indicate 
      that inhibition of this cytokine release is one of the important therapeutic 
      effects of Vancomycin in sepsis.
FAU - Siedlar, M
AU  - Siedlar M
AD  - Department of Clinical Immunology, Polish-American Children Hospital, Medical 
      Faculty, Jagiellonian University, Cracow, Poland.
FAU - Szczepanik, A
AU  - Szczepanik A
FAU - Wieckiewicz, J
AU  - Wieckiewicz J
FAU - Pituch-Noworolska, A
AU  - Pituch-Noworolska A
FAU - Zembala, M
AU  - Zembala M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Immunopharmacology
JT  - Immunopharmacology
JID - 7902474
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 6Q205EH1VU (Vancomycin)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Down-Regulation/*drug effects
MH  - Drug Interactions
MH  - Humans
MH  - Leukocytes, Mononuclear/*drug effects/*metabolism
MH  - Lipopolysaccharides/*pharmacology
MH  - Mice
MH  - RNA, Messenger/*metabolism
MH  - Stimulation, Chemical
MH  - Transcription, Genetic/drug effects
MH  - Tumor Necrosis Factor-alpha/*biosynthesis/metabolism
MH  - Vancomycin/*pharmacology
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - S0162310996001567 [pii]
AID - 10.1016/s0162-3109(96)00156-7 [doi]
PST - ppublish
SO  - Immunopharmacology. 1997 Jan;35(3):265-71. doi: 10.1016/s0162-3109(96)00156-7.